24-h monitoring of calcineurin phosphatase activity in healthy subjects

Scandinavian Journal of Immunology

Volumn 62, Issue 3, 2005, Pages 309-311

  Koefoed Nielsen, P B ^a   Karamperis, N ^a   Jorgensen K A ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CALCINEURIN INHIBITOR; CYCLOSPORIN; TACROLIMUS;

ADULT; ARTICLE; CALIBRATION; CIRCADIAN RHYTHM; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIQUID SCINTILLATION COUNTING; MALE; NORMAL HUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEX DIFFERENCE;

CALCINEURIN; CIRCADIAN RHYTHM; FEMALE; HUMANS; MALE; MONITORING, PHYSIOLOGIC; PHOSPHORIC MONOESTER HYDROLASES; SEX FACTORS;

EID: 26244454932     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2005.01660.x     Document Type: Article

References (17)

1. Opelz G. Collaborative Transplant Study - 10-year report. Transplant Proc 1992;24:2342-55.
2. Opelz G. Effect of immunosuppressive therapy on graft half-life projections. The Collaborative Transplant Study. Transplant Proc 1999;31:31S-33S.
3. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992;357:695-7.
4. Hemenway CS, Heitman J. Calcineurin. Structure, function, and inhibition. Cell Biochem Biophys 1999;30:115-51.
5. Jorgensen KA, Koefoed-Nielsen PB, Karamperis N. Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus. Scand J Immunol 2003;57:93-8.
6. Levy GA. C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation. Biodrugs 2001;15:279-90.
7. Oellerich M, Armstrong VW. Two-hour cyclosporine concentration determination: an appropriate tool to monitor neoral therapy? Ther Drug Monit 2002;24:40-6.
8. Yatscoff RW, Aspeslet LJ, Gallant HL. Pharmacodynamic monitoring of immunosuppressive drugs. Clin Chem 1998;44:428-32.
9. Dambrin C, Klupp J, Morris RE. Pharmacodynamics of immunosuppressive drugs. Curr Opin Immunol 2000;12:557-62.
10. Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999;68:1356-61.
11. Piccinini G, Gaspari F, Signorini O, Remuzzi G, Perico N. Recovery of blood mononuclear cell calcineurin activity segregates two populations of renal transplant patients with different sensitivities to cyclosporine inhibition. Transplantation 1996;61:1526-31.
12. Brunet M, Campistol JM, Millan O et al. Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C(2). Int Immunopharmacol 2003;3:987-99.
13. Koefoed-Nielsen PB, Gesualdo MB, Poulsen JH, Jorgensen KA. Blood tacrolimus levels and calcineurin phosphatase activity early after renal transplantation. Am J Transplant 2002;2:173-8.
14. Caruso R, Perico N, Cattaneo D et al. Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients. Clin Chem 2001;47:1679-87.
15. Fruman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci USA 1992;89:3686-90.
16. Koefoed-Nielsen PB, Karamperis N, Jorgensen KA. Validation of the calcineurin phosphatase assay. Clin Chem 2004;50:2331-7.
17. Pahlavani MA, Vargas DM. Age-related decline in activation of calcium/calmodulin-dependent phosphatase calcineurin and kinase CaMK-IV in rat T cells. Mech Ageing Dev 1999;112:59-74.